Mekinist is owned by Novartis.
Mekinist contains Trametinib Dimethyl Sulfoxide.
Mekinist has a total of 9 drug patents out of which 0 drug patents have expired.
Mekinist was authorised for market use on 29 May, 2013.
Mekinist is available in tablet;oral dosage forms.
Mekinist can be used as mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; treatment of unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; in combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection, mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection, mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test, mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.
The generics of Mekinist are possible to be released after 30 August, 2033.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(4 years from now) | |
US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(2 years from now) | |
US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(7 years from now) | |
US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
M | Oct 6, 2022 |
New Indication (I) | Jun 22, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; Treatment of unresectable or metastatic melanoma; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic